{"organizations": [], "uuid": "fb61cb6ec78ce6d92b5a35fe625bd64cf9f4102b", "thread": {"social": {"gplus": {"shares": 0}, "pinterest": {"shares": 0}, "vk": {"shares": 0}, "linkedin": {"shares": 0}, "facebook": {"likes": 0, "shares": 0, "comments": 0}, "stumbledupon": {"shares": 0}}, "site_full": "www.reuters.com", "main_image": "https://s4.reutersmedia.net/resources_v2/images/rcom-default.png", "site_section": "http://www.reuters.com/resources/archive/us/20180416.html", "section_title": "Archive News &amp; Video for Monday, 16 Apr 2018 | Reuters.com", "url": "https://www.reuters.com/article/us-bristol-myers-study/bristol-myers-says-cancer-drug-combo-reduces-death-risk-idUSKBN1HN1W2", "country": "US", "domain_rank": 408, "title": "Bristol-Myers says cancer drug combo reduces death risk", "performance_score": 0, "site": "reuters.com", "participants_count": 1, "title_full": "", "spam_score": 0.958, "site_type": "news", "published": "2018-04-16T21:51:00.000+03:00", "replies_count": 0, "uuid": "fb61cb6ec78ce6d92b5a35fe625bd64cf9f4102b"}, "author": "Reuters Editorial", "url": "https://www.reuters.com/article/us-bristol-myers-study/bristol-myers-says-cancer-drug-combo-reduces-death-risk-idUSKBN1HN1W2", "ord_in_thread": 0, "title": "Bristol-Myers says cancer drug combo reduces death risk", "locations": [], "entities": {"persons": [{"name": "yervoy", "sentiment": "negative"}, {"name": "manas mishra", "sentiment": "none"}, {"name": "keytruda", "sentiment": "none"}, {"name": "anil d'silva", "sentiment": "none"}], "locations": [{"name": "opdivo", "sentiment": "none"}, {"name": "bengaluru", "sentiment": "none"}], "organizations": [{"name": "reuters", "sentiment": "negative"}, {"name": "squibb", "sentiment": "negative"}, {"name": "merck & co", "sentiment": "none"}]}, "highlightText": "", "language": "english", "persons": [], "text": "(Reuters) - Bristol-Myers Squibb said on Monday its cancer drugs, Opdivo and Yervoy, reduced the risk of the disease spreading or death in previously untreated patients with a type of lung cancer.\nThe combination demonstrated a higher rate of progression-free survival, compared with chemotherapy in a late-stage trial, the company said.\nThe results come a week after rival Merck & Co said a trial testing its blockbuster drug Keytruda as a monotherapy in previously untreated lung cancer patients was successful.\nReporting by Manas Mishra in Bengaluru; Editing by Anil D'Silva\n ", "external_links": ["https://twitter.com/reuters", "https://www.youtube.com/user/ReutersVideo", "https://www.linkedin.com/company/10256858/", "https://www.facebook.com/Reuters", "https://www.thomsonreuters.com/en/privacy-statement.html", "http://thomsonreuters.com/en/about-us/trust-principles.html", "https://instagram.com/reuters/"], "published": "2018-04-16T21:51:00.000+03:00", "crawled": "2018-04-17T12:10:28.054+03:00", "highlightTitle": ""}